Viewing all links from the source for category: Pharma/Biotech

20/10/2025

Amplia Therapeutics to significantly expand US presence through expansion of clinical and investor facing activities

17/10/2025

Lumos Diagnostics enters agreement with WellStreet Urgent Care to advance FebriDx testing

Clarity signs copper-67 Supply Agreement with Nusano

First OncoSil treatment in Germany

Mayne Pharma: OUTCOME OF LITIGATION AND UPDATE ON SCHEME

16/10/2025

Sigma Healthcare runs ML in SAP for more forecasting gains

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

15/10/2025

Mayne Pharma annual report

Clarity Pharmaceuticals: Co-PSMA trial achieves primary endpoint

Nexsen sucessfully lists on ASX

Nexsen sucessfully lists on ASX

14/10/2025

Australian nano-biotech Nexsen Limited to debut on ASX with world-first diagnostic platform spanning human health, agriculture and biosecurity

Nyrada Selects Accelagen as CRO for Phase IIa Clinical Trial

$9.5M PLACEMENT AND $2M SPP TO ACCELERATE DEVELOPMENT OF INOVIQ’S OVARIAN CANCER TEST AND THERAPEUTIC PROGRAM

13/10/2025

Medicines Australia: Announcement by Astra Zeneca and US President Trump

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025

10/10/2025

AMPLIA THERAPEUTICS REPORTS ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL

BioMedTech Incubator Program Delivered by Brandon BioCatalyst’s CUREator and CSIRO Opens New Funding Round

09/10/2025

AusBiotech’s Annual Report captures a defining year for life sciences

LTR Pharma increases ownership in LevOmega to ~43% through strategic A$1m investment

01/10/2025

CLINUVEL to advance novel pharmaceutical formulations in preclinical program

MAYNE PHARMA ANNOUNCES PBS LISTING OF NEXTSTELLIS® IN AUSTRALIA

30/09/2025

Pfizer sued in US over contraceptive that women say caused brain tumours

Nyrada: Xolatryp™ Achieves Key Clinical Milestone

29/09/2025

Medicines Australia firmly oppose US tariffs on pharmaceuticals

INOVIQ LICENCES WORLDWIDE RIGHTS TO OVARIAN CANCER BIOMARKER IP FROM UNIQUEST

FDA takes close look at mifepristone REMS program after request from Republican AGs

26/09/2025

Recce: Patient Dosing and Multiple Sites Activated in Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia

Drug approval provides hope for people living with Alzheimer’s – Dementia Australia

Syntara receives A$5.6m R&D Tax Incentive

South Korea’s K-Bio Lab Hub forms MoU with Monash University – Monash University

Mayne Pharma director questioned management integrity, court hears

I-MED targets acquisitions, organic growth after failed takeover talks

24/09/2025

INOVIQ’S CAR-NK-EXOSOMES CONFIRMED TO KILL BREAST CANCER CELLS IN VITRO AT PETER MAC

Moderna: Australia’s mRNA Advantage: Jobs, Health and Economic Resilience

PERCHERON APPOINTS CHIEF MEDICAL OFFICER AND CHIEF TECHNOLOGY OFFICER TO PROGRESS HMBD-002

Clinuvel: EMA approves year-round SCENESSE® treatment

23/09/2025

CUREator+ delivers $15.7 m to local BioMedTech Startups Tackling the Global Dementia Challenge – Brandon BioCatalyst

LTR Pharma secures 33% ownership in LevOmega Pty Ltd

Starpharma Announces a Collaboration and License Agreement with Genentech to Develop Innovative DEP® Cancer Therapies

22/09/2025

Clinuvel: SCENESSE® efficacy in vitiligo: new cases presented to EADV

19/09/2025

Neurizon: R&D Tax Incentive Advance & Overseas Finding Approval

Imugene: Overall Response Rate (ORR) increases to 81% with two additional Partial Responses in azer-cel CAR T Phase 1b trial

Oncosil: Positive Preliminary Results from the PANCOSIL Phase 1-2 Study

18/09/2025

Orthocell: Globally significant opportunity emerges as Remplir is used in nerve-sparing prostate cancer surgery

Nyrada: Xolatryp™ Protects Cells through Mitochondrial Stabilisation

16/09/2025

AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe

10/09/2025

Lumos Diagnostics signs second ANZ distribution agreement for FebriDx

Telix and FDA Agree on Resubmission Pathway for TLX101-CDx (Pixclara®) U.S. NDA

Neuren partners with Hope for HIE to support development of NNZ-2591